New treatment option for HR+/HER2- breast cancer patients available in China.
- Sacituzumab tirumotecan receives NMPA approval for new indication.
- This treatment targets HR+/HER2- breast cancer.
- Kelun Biotech expands its oncology portfolio.
Kelun Biotech has announced that the National Medical Products Administration (NMPA) in China has approved sacituzumab tirumotecan for the treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. This marks the fourth indication for this therapy, expanding treatment options for patients dealing with this specific type of cancer. Sacituzumab tirumotecan represents a novel approach in oncology and aims to improve outcomes for patients.
The approval comes after initial indications highlighted the drug's effectiveness in various cancer types. With this new indication, healthcare providers now have another option to offer patients who may not have responded to traditional therapies. By adding this medication to the roster, Kelun Biotech continues to enhance its contributions to cancer treatment, emphasizing their commitment to addressing unmet medical needs.
This latest approval demonstrates ongoing progress in the fight against breast cancer, particularly in subtypes that require specialized treatment approaches. The addition of sacituzumab tirumotecan may help provide a much-needed lifeline for patients navigating the complexities of HR+/HER2- breast cancer. Kelun Biotech remains focused on advancing these therapies to benefit patients and healthcare providers.
